Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$602.02 USD
+3.99 (0.67%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $601.70 -0.32 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
CVS Health Retail Prescription Volume Grows Despite LTC Woes
by Zacks Equity Research
CVS Health's (CVS) consumer centric digital strategy has become even more relevant now.
Cardiovascular Systems Rides on Launches Amid Coronavirus Woes
by Zacks Equity Research
Cardiovascular Systems' (CSII) encouraging REACH PVI study outcome and launch of a physician finder are positives.
Boston Scientific Launches DBS System in Europe Post Approval
by Zacks Equity Research
Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP.
Varian (VAR) Expands Presence With Germany's Ethos Order
by Zacks Equity Research
Varian's (VAR) Ethos therapy is being adopted in Germany, thus expanding the company's geographic footprint.
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, Abbott, Quidel, QIAGEN and Thermo Fisher Scientific
Medtronic Receives FDA's Go Ahead for EFS Study on TTVR
by Zacks Equity Research
Medtronic (MDT) begins the FDA-approved EFS of Intrepid TTVR system following the receipt of the Breakthrough Device Designation from the regulatory authority.
National Vision Banks on Contact Lens Sales Amid Coronavirus Woes
by Zacks Equity Research
National Vision (EYE) sales bear the impact of unfavorable timing of unearned revenues.
Here's Why You Should Hold on to Medtronic Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Medtronic (MDT) on robust segmental growth and strong ventilators sales.
Here's Why You Should Retain AmerisourceBergen Stock Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches. However, stiff competition remains a woe.
Cerner (CERN) Inks Deal With Finland Regional Leadership
by Zacks Equity Research
Cerner (CERN) collaborates with Finland regional leadership to help bring integrated health and care.
CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day
by Zacks Equity Research
CHDN, AMC, FMS, OMI and TMO as Zacks Bull and Bear of the Day
Varian Expands Access to Advanced Cancer Treatment With Ethos
by Zacks Equity Research
Varian's (VAR) Ethos Therapy used by Goshen Center for Cancer Care marks the expansion access to personalized cancer care.
Coronavirus Test Makers With Scope to Maximize Investor Benefits
by Urmimala Biswas
The surge in new coronavirus infections broadens the scope for antigen and antibody tests.
Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement
by Zacks Equity Research
Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $419.73, marking a +0.34% move from the previous day.
Henry Schein Partners MouthWatch to Grow in Teledentistry
by Zacks Equity Research
Henry Schien's (HSIC) customer base is likely to benefit from the Teledent platform.
QIAGEN, Ellume Extend Alliance for COVID-19 Antigen Test
by Zacks Equity Research
QIAGEN (QGEN) extends partnership with Ellume to offer the second COVID-19 test utilizing the latter's technology and strengthening its own COVID-19-testing portfolio.
3 MedTech Outperformers to Grab Amid Coronavirus Pandemic
by Trina Mukherjee
Let's grab these three stocks that have shown tremendous promise amid the coronavirus pandemic.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Abbott Banks on EPD, Nutrition Growth to Beat Coronavirus Woes
by Zacks Equity Research
Abbott (ABT) expects to register strong growth for the second half of 2020 within established pharmaceuticals (EPD).
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q2.
PRA Health (PRAH) Inks Deal With Leukemia & Lymphoma Society
by Zacks Equity Research
PRA Health (PRAH) partners with LLS to bring new treatments for children with relapsed acute leukemia.
Bruker Banks on Strategic Innovation Amid Coronavirus Crisis
by Zacks Equity Research
At Bruker's (BRKR) Germany campus, the company currently offers a pilot COVID-19 at work testing program for its factory workforce.
Henry Schein (HSIC) Enters Into New Dental Deal With Zyris
by Zacks Equity Research
Henry Schien (HSIC) is set to be the exclusive distributor of Zyris products like Isolite 3, Isovac 2, Isodry and the company's patented single-use Mouthpieces.